REPORT ID 6550

EMEA (Europe, Middle East and Africa) Interleukin 1 (IL1) Market Report 2017

Publish Date
26-Dec-17
Pages
119
Format
Electronic (PDF)

In this report, the EMEA Interleukin 1 (IL1) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Interleukin 1 (IL1) for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Interleukin 1 (IL1) market competition by top manufacturers/players, with Interleukin 1 (IL1) sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Optimum Therapeutics LLC
    Orphit SAS
    Peptinov SAS
    AbbVie Inc
    Swedish Orphan Biovitrum AB
    TWi Biotechnology Inc
    XBiotech Inc
    Cell Medica Ltd
    Exicure Inc
    Immune Response BioPharma Inc
    Novartis AG
    Omnitura Therapeutics Inc
    Opsona Therapeutics Ltd
    Anacor Pharmaceuticals Inc
    Apexigen Inc
    R Pharm
    Regeneron Pharmaceuticals Inc

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    APX-002
    Canakinumab
    Diacerein CR
    IR-1000
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Esophageal Cancer
    Fallopian Tube Cancer
    Bladder Cancer
    Bechcer Disease
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Interleukin 1 (IL1) Market Report 2017
1 Interleukin 1 (IL1) Overview
    1.1 Product Overview and Scope of Interleukin 1 (IL1)
    1.2 Classification of Interleukin 1 (IL1)
        1.2.1 EMEA Interleukin 1 (IL1) Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Interleukin 1 (IL1) Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 APX-002
        1.2.4 Canakinumab
        1.2.5 Diacerein CR
        1.2.6 IR-1000
        1.2.7 Others
    1.3 EMEA Interleukin 1 (IL1) Market by Application/End Users
        1.3.1 EMEA Interleukin 1 (IL1) Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Esophageal Cancer
        1.3.3 Fallopian Tube Cancer
        1.3.4 Bladder Cancer
        1.3.5 Bechcer Disease
        1.3.6 Others
    1.4 EMEA Interleukin 1 (IL1) Market by Region
        1.4.1 EMEA Interleukin 1 (IL1) Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Interleukin 1 (IL1) (2012-2022)
        1.5.1 EMEA Interleukin 1 (IL1) Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Interleukin 1 (IL1) Revenue and Growth Rate (2012-2022)

2 EMEA Interleukin 1 (IL1) Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Interleukin 1 (IL1) Market Competition by Players/Manufacturers
        2.1.1 EMEA Interleukin 1 (IL1) Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Interleukin 1 (IL1) Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Interleukin 1 (IL1) Sale Price by Players (2012-2017)
    2.2 EMEA Interleukin 1 (IL1) (Volume and Value) by Type/Product Category
        2.2.1 EMEA Interleukin 1 (IL1) Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Interleukin 1 (IL1) Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Interleukin 1 (IL1) Sale Price by Type (2012-2017)
    2.3 EMEA Interleukin 1 (IL1) (Volume) by Application
    2.4 EMEA Interleukin 1 (IL1) (Volume and Value) by Region
        2.4.1 EMEA Interleukin 1 (IL1) Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Interleukin 1 (IL1) Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Interleukin 1 (IL1) Sales Price by Region (2012-2017)

3 Europe Interleukin 1 (IL1) (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Interleukin 1 (IL1) Sales and Value (2012-2017)
        3.1.1 Europe Interleukin 1 (IL1) Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Interleukin 1 (IL1) Revenue and Growth Rate (2012-2017)
    3.2 Europe Interleukin 1 (IL1) Sales and Market Share by Type
    3.3 Europe Interleukin 1 (IL1) Sales and Market Share by Application
    3.4 Europe Interleukin 1 (IL1) Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Interleukin 1 (IL1) Sales Volume by Countries (2012-2017)
        3.4.2 Europe Interleukin 1 (IL1) Revenue by Countries (2012-2017)
        3.4.3 Germany Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        3.4.4 France Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        3.4.5 UK Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        3.4.6 Russia Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        3.4.7 Italy Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)

4 Middle East Interleukin 1 (IL1) (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Interleukin 1 (IL1) Sales and Value (2012-2017)
        4.1.1 Middle East Interleukin 1 (IL1) Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Interleukin 1 (IL1) Revenue and Growth Rate (2012-2017)
    4.2 Middle East Interleukin 1 (IL1) Sales and Market Share by Type
    4.3 Middle East Interleukin 1 (IL1) Sales and Market Share by Application
    4.4 Middle East Interleukin 1 (IL1) Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Interleukin 1 (IL1) Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Interleukin 1 (IL1) Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        4.4.4 Israel Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        4.4.5 UAE Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        4.4.6 Iran Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)

5 Africa Interleukin 1 (IL1) (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Interleukin 1 (IL1) Sales and Value (2012-2017)
        5.1.1 Africa Interleukin 1 (IL1) Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Interleukin 1 (IL1) Revenue and Growth Rate (2012-2017)
    5.2 Africa Interleukin 1 (IL1) Sales and Market Share by Type
    5.3 Africa Interleukin 1 (IL1) Sales and Market Share by Application
    5.4 Africa Interleukin 1 (IL1) Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Interleukin 1 (IL1) Sales Volume by Countries (2012-2017)
        5.4.2 Africa Interleukin 1 (IL1) Revenue by Countries (2012-2017)
        5.4.3 South Africa Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Interleukin 1 (IL1) Sales and Growth Rate (2012-2017)

6 EMEA Interleukin 1 (IL1) Manufacturers/Players Profiles and Sales Data
    6.1 Optimum Therapeutics LLC
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Optimum Therapeutics LLC Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Orphit SAS
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Orphit SAS Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Peptinov SAS
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Peptinov SAS Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 AbbVie Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 AbbVie Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Swedish Orphan Biovitrum AB
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 TWi Biotechnology Inc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 TWi Biotechnology Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 XBiotech Inc
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 XBiotech Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Cell Medica Ltd
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Cell Medica Ltd Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Exicure Inc
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Exicure Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Immune Response BioPharma Inc
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Interleukin 1 (IL1) Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Immune Response BioPharma Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Novartis AG
    6.12 Omnitura Therapeutics Inc
    6.13 Opsona Therapeutics Ltd
    6.14 Anacor Pharmaceuticals Inc
    6.15 Apexigen Inc
    6.16 R Pharm
    6.17 Regeneron Pharmaceuticals Inc

7 Interleukin 1 (IL1) Manufacturing Cost Analysis
    7.1 Interleukin 1 (IL1) Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Interleukin 1 (IL1)

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Interleukin 1 (IL1) Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Interleukin 1 (IL1) Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Interleukin 1 (IL1) Market Forecast (2017-2022)
    11.1 EMEA Interleukin 1 (IL1) Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Interleukin 1 (IL1) Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Interleukin 1 (IL1) Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Interleukin 1 (IL1) Price and Trend Forecast (2017-2022)
    11.2 EMEA Interleukin 1 (IL1) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Interleukin 1 (IL1) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Interleukin 1 (IL1) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Interleukin 1 (IL1) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Interleukin 1 (IL1) Sales Forecast by Type (2017-2022)
    11.7 EMEA Interleukin 1 (IL1) Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer